BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Rosa-Neto P" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Associations between brain and cognitive resilience, tau load and extent in Alzheimer's disease | Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; | 41512332 PERFORM |
| 2 | Alzheimer s Imaging Consortium | Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; | 41433447 PERFORM |
| 3 | Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact | Seixas-Lima B; Rosa-Neto P; Phillips NA; Borrie M; Roncero CT; Lahiri D; Dori D; Eintracht S; Chertkow H; | 41358624 PSYCHOLOGY |
| 4 | The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterbe | 41020412 SOH |
| 5 | The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterberg H; S | 40778177 PSYCHOLOGY |
| 6 | Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research | Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; | 39893139 CONCORDIA |
| 7 | Alzheimer's Imaging Consortium | Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; | 39782975 CONCORDIA |
| 8 | Biomarkers | Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; | 39784152 CONCORDIA |
| 9 | Basic Science and Pathogenesis | Lima BS; Rosa-Neto P; Phillips N; Borrie M; Roncero CT; Lahiri D; Dori D; Chertkow H; | 39751468 CONCORDIA |
| 10 | Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) | Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; | 39636028 HKAP |
| 11 | Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status | Wearn A; Tremblay SA; Tardif CL; Leppert IR; Gauthier CJ; Baracchini G; Hughes C; Hewan P; Tremblay-Mercier J; Rosa-Neto P; Poirier J; Villeneuve S; Schmitz TW; Turner GR; Spreng RN; | 38830849 SOH |
| 12 | Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation | Scala SG; Kang MS; Cox SML; Rosa-Neto P; Massarweh G; Leyton M; | 38221806 CSBN |
| 13 | Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis | Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; | 38006502 PERFORM |
| 14 | Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum | Belasso CJ; Cai Z; Bezgin G; Pascoal T; Stevenson J; Rahmouni N; Tissot C; Lussier F; Rosa-Neto P; Soucy JP; Rivaz H; Benali H; | 37920382 PERFORM |
| 15 | Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors | Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A; | 35420022 PERFORM |
| 16 | Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [(18)F]-FEOBV | Legault-Denis C; Aghourian M; Soucy JP; Rosa-Neto P; Dagher A; Aumont E; Wickens R; Bedard MA; | 34628195 PERFORM |
| 17 | CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment | Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; | 33532543 PERFORM |
| 18 | Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. | DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E | 33401137 PERFORM |
| 19 | Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. | Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants | 32725777 PERFORM |
| 20 | Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment | Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, | 32582834 PERFORM |
| 21 | Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. | Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C | 32559027 CSBN |
| 22 | Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. | Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P | 31530809 PERFORM |
| 23 | Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study. | Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E | 31507359 PERFORM |
| 24 | Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging. | DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E | 27578494 PERFORM |
| 25 | Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. | Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA | 28894304 PERFORM |
| 26 | Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. | Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative | 29396637 PERFORM |
| Title: | The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond | ||||
| Authors: | Villeneuve S, Poirier J, Breitner JCS, Tremblay-Mercier J, Remz J, Raoult JM, Yakoub Y, Gallego-Rudolf J, Qiu T, Valdez AF, Mohammediyan B, Javanray M, Metz A, Sanami S, Ourry V, Wearn A, Pastor-Bernier A, Edde M, Gonneaud J, Strikwerda-Brown C, Tardif CL, Gauthier CJ, Descoteaux M, Dadar M, Vachon-Presseau É, Baril AA, Ducharme S, Montembeault M, Geddes MR, Soucy JP, Rajah N, Laforce R, Bocti C, Davatzikos C, Bellec L, Rosa-Neto P, Baillet S, Evans AC, Collins DL, Chakravarty MM, Blennow K, Zetterberg H, S | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/40778177/ | ||||
| DOI: | 10.1101/2025.07.22.25331791 | ||||
| Publication: | medRxiv : the preprint server for health sciences | ||||
| Keywords: | Biomarkers; clinical progression; cognition; data repository; neuroimaging; preclinical; | ||||
| PMID: | 40778177 | Category: | Date Added: | 2025-08-19 | |
| Dept Affiliation: |
PSYCHOLOGY
1 StoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada. 2 Department of Psychiatry, McGill University, Montréal, QC H3A 1A1, Canada. 3 McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada. 4 Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada. 5 Integrated Program in Neuroscience, McGill University, Montréal, QC H3A 0G4, Canada. 6 Research Center of the CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal, Montreal, QC H4J 1C5, Canada. 7 Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada. 8 Department of Physics, Concordia University, Montréal, QC H4B 1R6, Canada. 9 Department of Neurology and Neurosurgery, McGill University, Montréal, QC H3A 1A1, Canada. 10 Faculté des sciences, Département d'informatique, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada. 11 Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", NeuroPresage Team, GIP Cyceron, 14032 Caen, France. 12 School of Psychological Science, The University of Western Australia, Perth, Western Australia 6009, Australia. 13 Department Biomedical Engineering, McGill University, Montréal, QC H3A 2B4, Canada. 14 Centre ÉPIC, Montreal Heart Institute, Montréal, QC H1T 1N6, Canada. 15 Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada. 16 Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada. 17 Alan Edwards Center for Research on Pain, McGill University, Montreal, QC H3A 2B4, Canada. 18 Department of Psychology, Toronto Metropolitan University, Toronto, ON M5S 2E5, Canada. 19 Clinique interdisciplinaire de mémoire, CHU de Québec affilié à l'Université Laval, Québec, QC G1V 4G2, Canada. 20 Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada. 21 AI2D Center for AI and Data Science for Integrated Diagnostics, University of Pennsylvania, Philadelphia, PA 19104, USA. 22 Psychology Department, Université de Montréal, Montréal, QC H2V 2S9, Canada. 23 Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC H3W 1W5, Canada. 24 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 431 39 Mölndal, Sweden. 25 Clinical Neurochemistry Lab, Sahlgrenska University Hospital, 43180 Mölndal, Sweden. 26 Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France. 27 Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, Anhui, 230026 P.R. China. 28 Department of Neurodegenerative Disease, University College London Institute of Neurology, London WC1E 6BT, UK. 29 UK Dementia Research Institute at UCL, London NW1 3BT, UK. 30 Hong Kong Center for Neurodegenerative Diseases, InnoHK, 999077 Hong Kong, China. 31 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA. 32 Department of Physiology and Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada. 33 Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, 224 41 Lund, Sweden. |
||||
Description: |
The PREVENT-AD is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years [median follow-up 8.0 years,SD 3.1]. Multimodal MRI, genetic, neurosensory, clinical, cerebrospinal fluid and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau PET, magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection. |
